Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
175 participants
OBSERVATIONAL
2016-10-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An important inter-individual variability in humoral immune response suggests that vaccination should be recommended in exposed subjects.
This cohort study aimed to determine if subjects that have been infected by leptospirosis for 1 to 7 years still remain immunized, and then do not need vaccination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
NCT02000635
Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI
NCT06945822
Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO
NCT05413720
Cohort of Hospitalized Patients Suspected of Leptospirosis
NCT04034550
Cerebral Toxoplasmosis and AIDS
NCT00803621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cured subjects that have been infected for 1, 2, 3, 4, 5, 6 or 7 years will be enrolled. The qualitative and quantitative humoral immune response to leptospirosis infection will also be evaluated to determine whether they still get protective immunization. Leptospirosis immunization will be evaluated using micro-agglutination test.
Graded immune responses related to the severity and the length of the infection will also be investigated.
Finally, 3 methods used for leptospirosis diagnosis will be compared. It is expected from this study to evaluate the appropriate conditions in which new vaccination could be required to prevent further leptospirosis infection in cured subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cohort
Blood sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with social security issue
Exclusion Criteria
* subject exhibiting immunodepressive status (cancers, transplantation, immune deficit, blood disorders)
* under medication: corticoids, immunosuppressor, chemiotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
Centre Hospitalier Universitaire de la Réunion
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NICOLAS TRAVERSIER, MD
Role: PRINCIPAL_INVESTIGATOR
CHU DE LA REUNION
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015/CHU/07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.